home / stock / hoth / hoth news


HOTH News and Press, Hoth Therapeutics Inc.

Stock Information

Company Name: Hoth Therapeutics Inc.
Stock Symbol: HOTH
Market: NASDAQ
Website: hoththerapeutics.com

Menu

HOTH HOTH Quote HOTH Short HOTH News HOTH Articles HOTH Message Board
Get HOTH Alerts

News, Short Squeeze, Breakout and More Instantly...

HOTH - Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program

Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program PR Newswire AI Integration Supports IND Preparation & Phase 1 Progression for Rare KIT-Driven Cancers NEW YORK , March 4, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDA...

HOTH - HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES

HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES PR Newswire CLEER-001 Phase 2a Expansion Signals Growing Momentum Behind First-in-Class Therapy for Cancer Patients With No Current FDA-Approved Treatment Option NEW YORK , ...

HOTH - Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases

Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases PR Newswire Patent Covers Combination of FC Epsilon RI-Beta Exon Skipping and MS4A6A Modulation — Strengthening Hoth's Immunology IP Portfolio NEW YORK , Feb. ...

HOTH - Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model PR Newswire In a head-to-head preclinical comparison, HT-VA co-developed with the United States Veterans Administr...

HOTH - Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets

Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets PR Newswire NEW YORK , Feb. 5, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH),  a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer pa...

HOTH - Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients PR Newswire Primary endpoint ARIGA improved by ~50% from baseline by Week 6, with all evaluable patients reaching low-severity disease; ...

HOTH - Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position

Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position PR Newswire Chinese Patent Approved Covering HT-KIT Technology Designed to Induce Cancer Cell Apoptosis, Expanding Protection in One of the World's L...

HOTH - Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation

Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation PR Newswire Positive EU regulatory conclusion achieved Oncology-focused clinical program Multi-country European trial footprint Clear line of si...

HOTH - Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform

Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform PR Newswire NEW YORK , Jan. 2, 2026 /PRNewswire/ -- Hoth Therapeutics  (NASDAQ: HOTH) , a clinical-stage biopharmaceutical company developing inno...

HOTH - Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program PR Newswire NEW YORK , Dec. 3, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) , a patient-fo...

Next 10